2025

（原著論文）

• Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials.
  Kawasaki A, Shintani R, Takao R, Nakazawa Y, Mihara T, Ikegami S, Shimada S, Matsumoto Y, Okamoto Y, Igarashi Y, Enoki Y, Taguchi K, Matsumoto K.
  Med Mycol. 2025; 63(10): myaf089. Abstract
• Oral β-lactam combinations are effective in vitro against Mycobacterium avium, regardless of clarithromycin susceptibility.
  Yoshikawa M, Nishimura T, Misawa K, Shimamura R, Suzuki K, Kashimura S, Igarashi Y, Enoki Y, Taguchi K, Hasegawa N, Namkoong H, Matsumoto K.
  Microbiol Spectr. 2025; 13(11): e0201225. Abstract
• Prediction of treatment success in patients with Enterococcus faecium bacteremia using vancomycin AUC₂₄/MIC ratio: A multicenter retrospective study.
  Hanai Y, Matsumoto K, Hanawa K, Endo A, Hashi H, Miyazaki T, Yamaguchi T, Harada S, Yokoo T, Uekusa S, Yokoyama Y, Maruyama R, Tsujimura S, Asakawa D, Namiki T, Isoda R, Enoki Y, Taguchi K, Matsuo K.
  Diagn Microbiol Infect Dis. 2025; 113(2): 116961. Abstract
• Risk stratification of AUC upward deviation in patients with low serum creatinine levels treated with vancomycin: a multicenter retrospective study.
  Ishigo T, Suzuki A, Ibe Y, Fujii S, Fukudo M, Yoshida H, Tanaka H, Fujihara H, Yamaguchi F, Ebihara F, Maruyama T, Hamada Y, Samura M, Nagumo F, Komatsu T, Tomizawa A, Takuma A, Chiba H, Nishi Y, Enoki Y, Taguchi K, Matsumoto K.
  J Pharm Pharmacol. 2025; 77(9): 1255-1263. Abstract
• CKD-Induced Oxidative Twitch Muscle Atrophy Is Mediated by TGF- β.
  Homma K, Enoki Y, Taguchi K, Matsumoto K.
  Kidney360. 2025; 6(9): 1438-1447. Abstract
• Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium.
  Hayashi Y, Takahashi M, Sasaki M, Suzuki K, Mizukami Y, Liu X, Enoki Y, Taguchi K, Yamaguchi T, Tateda K, Matsumoto K.
  J Antimicrob Chemother. 2025; 80(8): 2092-2099. Abstract
• Shortening the interval between the first and the second dose of vancomycin facilitates rapid achievement of the target AUC without increasing the risk of acute kidney injury, provided the AUC on the second day is appropriately controlled: a multicenter retrospective study.
  Ishigo T, Suzuki A, Ibe Y, Fujii S, Fukudo M, Yoshida H, Tanaka H, Fujihara H, Yamaguchi F, Ebihara F, Maruyama T, Hamada Y, Yagi Y, Samura M, Nagumo F, Komatsu T, Tomizawa A, Takuma A, Chiba H, Nishi Y, Enoki Y, Taguchi K, Matsumoto K.
  J Pharm Health Care Sci. 2025; 11(1): 44. Abstract
• Methemoglobin-Encapsulating Liposome: A Low-Risk Intravascular Contrast Agent for Magnetic Resonance Imaging.
  Taguchi K, Sumiyoshi A, Suzuki Y, Ozawa Y, Iiyama M, Gao S, Sakai H, Osada K, Matsumoto K, Aoki I.
  ACS Appl Bio Mater. 2025; 8(4): 2838-2846. Abstract
• Development and validation of a population pharmacokinetic model of vancomycin for patients of advanced age.
  Takada K, Samura M, Igarashi Y, Suzuki A, Ishigo T, Fujii S, Ibe Y, Yoshida H, Tanaka H, Ebihara F, Maruyama T, Hamada Y, Komatsu T, Tomizawa A, Takuma A, Chiba H, Yagi Y, Nishi Y, Enoki Y, Taguchi K, Tanikawa K, Kunishima H, Matsumoto K.
  J Pharm Health Care Sci. 2025; 11(1): 18. Abstract
• Combined dual β-lactams and diazabicyclooctane β-lactamase inhibitor is highly effective against Mycobacterium abscessus species in vitro.
  Misawa K, Nishimura T, Yoshikawa M, Shimamura R, Kashimura S, Enoki Y, Taguchi K, Matsumoto K, Hasegawa N.
  J Glob Antimicrob Resist. 2025; 42: 142-150. Abstract
• Carbon monoxide alleviates endotoxin-induced acute lung injury via NADPH oxidase inhibition in macrophages and neutrophils.
  Watabe Y, Giam Chuang VT, Sakai H, Ito C, Enoki Y, Kohno M, Otagiri M, Matsumoto K, Taguchi K.
  Biochem Pharmacol. 2025; 233: 116782. Abstract
• Treatment success prediction in patients with methicillin-resistant coagulase-negative staphylococci infections, using vancomycin AUC24/MIC ratio: a multicentre retrospective cohort study.
  Hanai Y, Matsumoto K, Endo A, Hanawa K, Hashi H, Miyazaki T, Yamaguchi T, Harada S, Yokoo T, Uekusa S, Asakawa D, Yokoyama Y, Maruyama R, Tsujimura S, Namiki T, Isoda R, Enoki Y, Taguchi K, Matsuo K.
  J Antimicrob Chemother. 2025; 80(2): 538-546. Abstract
• Simulated achievement rate of β-lactams/nacubactam treatment in humans using instantaneous MIC-based PK/PD analysis.
  Igarashi Y, Taguchi K, Enoki Y, Chuang VTG, Matsumoto K.
  J Antimicrob Chemother. 2025; 80(2): 547-553. Abstract
• One-Step Maleimide-Based Dual Functionalization of Protein N-Termini.
  Hanaya K, Taguchi K, Wada Y, Kawano M.
  Angew Chem Int Ed Engl. 2025; 64(5): e202417134. Abstract
• Development of a pharmacokinetic/pharmacodynamic evaluation model for osteomyelitis and usefulness of tedizolid as an alternative to vancomycin against MRSA osteomyelitis.
  Liu X, Enoki Y, Taguchi K, Matsumoto K.
  J Pharm Pharmacol. 2025; 77(2): 291-298. Abstract
• SARS-CoV-2 mRNA vaccine-related myocarditis and pericarditis: An analysis of the Japanese Adverse Drug Event Report database.
  Takada K, Taguchi K, Samura M, Igarashi Y, Okamoto Y, Enoki Y, Tanikawa K, Matsumoto K.
  J Infect Chemother. 2025; 31(1): 102485. Abstract
• Direct comparison of the effects of first- and second-generation H₁ -receptor blockers on motor functions in mice.
  Taguchi K, Tenjin K, Sakamoto Y, Shimada A, Hara R, Iketani O, Okamoto Y, Enoki Y, Kizu J, Hori S, Matsumoto K.
  Pharmazie. 2025; 80(1): 24-28. Abstract
• 医療用一般用共用医薬品（仮称）の創設提言に対する薬剤師の認知および見解に関する実態把握調査
  岡本 侑子, 田口 和明, 榎木 裕紀, 堀 里子, 山浦 克典, 松元 一明
  医療薬学, 2025; 51(4): 196-202 Abstract